RIFAMPIN AND ISONIAZID Drug Patent Profile
✉ Email this page to a colleague
When do Rifampin And Isoniazid patents expire, and when can generic versions of Rifampin And Isoniazid launch?
Rifampin And Isoniazid is a drug marketed by Hikma Intl Pharms and is included in one NDA.
The generic ingredient in RIFAMPIN AND ISONIAZID is isoniazid; rifampin. There are five drug master file entries for this compound. Additional details are available on the isoniazid; rifampin profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RIFAMPIN AND ISONIAZID?
- What are the global sales for RIFAMPIN AND ISONIAZID?
- What is Average Wholesale Price for RIFAMPIN AND ISONIAZID?
Summary for RIFAMPIN AND ISONIAZID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 56 |
| Patent Applications: | 299 |
| DailyMed Link: | RIFAMPIN AND ISONIAZID at DailyMed |
Recent Clinical Trials for RIFAMPIN AND ISONIAZID
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | PHASE3 |
| University of Virginia | PHASE3 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | PHASE2 |
US Patents and Regulatory Information for RIFAMPIN AND ISONIAZID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma Intl Pharms | RIFAMPIN AND ISONIAZID | isoniazid; rifampin | CAPSULE;ORAL | 065221-001 | Jul 29, 2005 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
